Corcept Therapeutics Incorporated
$ 82.65
-1.12%
26 Dec - close price
- Market Cap 8,708,974,000 USD
- Current Price $ 82.65
- High / Low $ 83.70 / 82.13
- Stock P/E 95.00
- Book Value 6.01
- EPS 0.87
- Next Earning Report 2026-02-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.17 %
- 52 Week High 117.33
- 52 Week Low 49.00
About
Corcept Therapeutics Incorporated is a biopharmaceutical company headquartered in Menlo Park, California, specializing in the development of innovative therapies that modulate cortisol levels to address severe metabolic, psychiatric, and oncological disorders. The company employs a proprietary approach targeting significant unmet medical needs, bolstered by a robust pipeline of product candidates aimed at improving patient outcomes. As Corcept progresses through its clinical programs, it is well-positioned to create substantial value for both patients and shareholders by fulfilling critical treatment gaps in these therapeutic areas.
Analyst Target Price
$127.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-08-02 | 2023-05-03 | 2023-02-28 |
| Reported EPS | 0.16 | 0.29 | 0.1693 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 | 0.14 | 0.14 |
| Estimated EPS | 0.13 | 0.1864 | 0.1425 | 0.4233 | 0.28 | 0.23 | 0.22 | 0.26 | 0.22 | 0.15 | 0.19 | 0.23 |
| Surprise | 0.03 | 0.1036 | 0.0268 | -0.1633 | 0.13 | 0.09 | 0.03 | 0.02 | 0.06 | 0.1 | -0.05 | -0.09 |
| Surprise Percentage | 23.0769% | 55.5794% | 18.807% | -38.5778% | 46.4286% | 39.1304% | 13.6364% | 7.6923% | 27.2727% | 66.6667% | -26.3158% | -39.1304% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.3407 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2025-12-27 09:08:20
Burney Co. significantly reduced its stake in Corcept Therapeutics (NASDAQ:CORT) by selling 19,381 shares, now owning 230,765 shares valued at $19.2 million. This comes amid substantial insider selling from the CEO and a director totaling over $21 million, though insiders still hold 20.8% of the company. Analysts are divided on the stock with a "Moderate Buy" consensus, despite the company missing recent EPS and revenue estimates, even with a 13.8% year-over-year revenue growth.
2025-12-25 21:09:34
Corcept Therapeutics (CORT) is facing increased investor scrutiny due to the upcoming U.S. FDA decision on relacorilant, a drug with mixed late-stage trial results. This regulatory uncertainty is highlighted as a significant factor shaping the company's investment narrative, particularly concerning its diversification efforts beyond its core hypercortisolism franchise. The outcome will heavily influence Corcept's future revenue streams and its ability to reduce reliance on its existing drug, Korlym.
2025-12-25 20:42:42
Corcept Therapeutics is facing scrutiny due to an upcoming FDA decision on relacorilant, which has a mixed trial record. This decision is crucial for Corcept's strategy to diversify its revenue beyond its core hypercortisolism franchise and current drug Korlym. Analysts have already cut sales expectations, reflecting the high stakes of the regulatory outcome on the company's investment narrative and future growth.
2025-12-24 21:09:42
Shares of Corcept Therapeutics (NASDAQ:CORT) dropped 4.7% as the company awaits an FDA decision on its drug candidate, relacorilant, by December 30, 2025. The market is showing anxiety due to mixed trial results and recent analyst downgrades, even though the stock has seen significant year-to-date performance. The outcome of the FDA decision is critical, as it could substantially impact Corcept's valuation given its limited drug pipeline.
2025-12-23 15:51:00
Corcept Therapeutics (NASDAQ:CORT) shares fell by 4.7% due to escalating investor anxiety ahead of a critical FDA decision for its drug candidate, relacorilant, scheduled for December 30, 2025. Although one late-stage trial met its primary goal, the failure of another trial raised concerns about a potential Complete Response Letter from the FDA, posing a significant risk to the company's valuation. This follows a previous drop after UBS initiated coverage with a Neutral rating, projecting 2030 sales below consensus.
2025-12-21 22:09:59
Corcept Therapeutics (CORT) has seen a significant share price surge of 68% year-to-date, outperforming the broader market. Despite this, the stock is considered 34.2% undervalued by analysts, with a consensus price target of $134.5, although there's disagreement among them. However, a high P/E ratio compared to peers suggests the market may already be pricing in substantial future growth.
